This ICK demonstrated improved tolerability, pharmacokinetics and tumor targeting as well as preferential activation of CD8+ and NK immune effector cells over Tregs as compared with its wild-type IL-2-based counterpart (14). The gene discussed is CD8A; the disease is neoplasm.